Breast cancer claims approximately 670,000 lives each year, making it the most common cancer in women in 157 out of 185 countries as per the latest data from the World Health Organization (WHO) in 2022. Over 2 million women are diagnosed with breast cancer annually, underlining the urgent need for early detection and targeted treatment. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for early-stage breast cancer treatment in combination with hormone therapy. This approval is particularly beneficial for patients concerned about cancer recurrence. FDA's official statement announced the approval of ribociclib in combination with an aromatase inhibitor for adjuvant treatment in adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. Additionally, FDA approved the combination of ribociclib and letrozole for the same indication in a co-pack named Kisqali Femara Co-Pack.
Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor that works by inhibiting two proteins, cyclin-dependent kinase 4 and 6 (CDK4/6), which, when overactive, promote rapid growth and division of cancer cells. By targeting CDK4/6, Kisqali helps slow down cancer progression by preventing uncontrollable cell replication.
Kisqali will be administered orally in the form of a pill, to be taken for three weeks followed by a one-week break, and continued for a total of three years. It can be taken with or without food, with a recommended daily oral dose of 400 mg.Kisqali Edition: Adverse Effects
The typical side effects linked with the medication Kisqali include reduced white blood cell count or neutropenia. Neutropenia arises when there is a depletion of neutrophils in the bloodstream, which are crucial for combating infections in the body. Additionally, another possible side effect of Kisqali is liver complications and interstitial lung disease/pneumonitis.
Breast Cancer: Warning Signs of the Condition Not to be Overlooked
